Recent Updates — EDVA
On October 22, 2026, Endovia Health Sciences entered into an addendum to its Securities Purchase Agreement with C/M Capital Master Fund, LP. The amendment increases the maximum commitment amount under the equity line of credit facility from $35 million to $135 million, inclusive of prior sales. Updated terms apply to future share issuances exceeding the initial 10,875,000 shares already sold under the original agreement filed in September 2025. Endovia Health Sciences operates in the healthcare sector.
On October 15, 2026, Endovia Health Sciences entered into a letter agreement with C/M Capital Master Fund, LP to amend its existing Securities Purchase Agreement. The amendment increases the investor's beneficial ownership limitation from 4.99% to 9.99%, effective immediately. Additionally, the parties waived notice requirements and other provisions of the original agreement that are inconsistent with this change. Endovia Health Sciences operates in the healthcare sector.
On September 30, 2026, Endovia Health Sciences sold and issued 526,582 shares of common stock to C/M Capital Master Fund, LP. The transaction was executed pursuant to a Securities Purchase Agreement dated September 19, 2025, generating total gross proceeds of $81,830.84. The sale relied on the exemption from registration under Section 4(a)(2) and Rule 506(b). This issuance is part of an existing Equity Line of Credit (ELOC) agreement previously disclosed in September 2025. Endovia Health Sciences operates in the healthcare sector, focusing on medical device innovation.
The U.S. Food and Drug Administration determined that Endovia Health Sciences' investigational cannabinoid oral solution, CannEpil®, qualifies as a minor use for controlling pain associated with bone cancer in dogs under the Minor Use and Minor Species program. This status establishes eligibility for the conditional approval pathway, allowing commercialization while additional effectiveness data is collected post-approval. The company plans to meet with the FDA on November 19, 2026, for a Pre-Submission Conference to align on development requirements and is finalizing U.S.-based manufacturing capabilities to support a potential veterinary launch in 2027. Endovia Health Sciences operates as a cannabinoid health sciences company focused on pharmaceutical development and FDA-regulated therapeutics.
Endovia Health Sciences entered into a Letter Agreement with C/M Capital Master Fund to invest a minimum of $1 million for the regulatory and commercial development of CannEpil. The company closed an initial investment of $510,000 in exchange for a secured convertible promissory note with a principal amount of $576,271. This debt instrument converts into common stock at the lower of $1.75 or $0.01 above the closing price and matures on September 18, 2027. Additionally, the company issued 3,629,250 shares under an existing equity line of credit for gross proceeds of $808,829.42 between August 31 and September 23, 2026. Endovia Health Sciences operates in the pharmaceutical industry, focusing on the development and commercialization of medical treatments.
Endovia Health Sciences, Inc. closed an initial $500,000 tranche of secured convertible debt financing from C/M Capital Master Fund, LP on September 22, 2026. This amount represents the first portion of a previously announced aggregate $1 million investment commitment intended to support the regulatory advancement and commercialization of CannEpil®, an exclusive global license acquired from Argent BioPharma Limited. The capital will fund Endovia’s U.S. FDA-regulated veterinary development program for canine oncology pain management, in collaboration with Lupvindol Biosciences Ltd., as well as international commercialization initiatives. The company operates in the cannabinoid health sciences industry, focusing on pharmaceutical development and therapeutics.